See more : China Best Group Holding Limited (0370.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Cullinan Oncology, Inc. (CGEM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cullinan Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- BCE Inc (BCCCF) Income Statement Analysis – Financial Results
- Orbit Exports Limited (ORBTEXP.BO) Income Statement Analysis – Financial Results
- Posco Dx Company Ltd. (022100.KS) Income Statement Analysis – Financial Results
- FinTech Evolution Acquisition Group (FTEV-UN) Income Statement Analysis – Financial Results
- Austin Engineering Company Limited (AUSTENG.BO) Income Statement Analysis – Financial Results
Cullinan Oncology, Inc. (CGEM)
About Cullinan Oncology, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 18.94M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 310.00K | 93.00K | 53.00K | 62.00K | 70.00K | 43.00K |
| Gross Profit | -310.00K | -93.00K | 18.89M | -62.00K | -70.00K | -43.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.72% | 0.00% | 0.00% | 0.00% |
| Research & Development | 148.16M | 91.95M | 57.75M | 43.21M | 16.79M | 9.58M |
| General & Administrative | 42.49M | 40.19M | 29.15M | 17.12M | 5.48M | 5.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.49M | 40.19M | 29.15M | 17.12M | 5.48M | 5.00M |
| Other Expenses | 440.00K | 57.00K | -8.00K | -11.00K | -4.00K | 0.00 |
| Operating Expenses | 191.09M | 132.14M | 86.90M | 60.34M | 22.27M | 14.59M |
| Cost & Expenses | 191.09M | 132.14M | 86.90M | 60.34M | 22.27M | 14.59M |
| Interest Income | 21.63M | 6.61M | 477.00K | 888.00K | 620.00K | 397.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 310.00K | 93.00K | 53.00K | 62.00K | 70.00K | 43.00K |
| EBITDA | -190.34M | 151.41M | -67.90M | -60.27M | -22.20M | -14.54M |
| EBITDA Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% | 0.00% |
| Operating Income | -191.09M | 144.65M | -67.95M | -60.34M | -22.27M | -14.59M |
| Operating Income Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 21.87M | 6.67M | 469.00K | 877.00K | 616.00K | 397.00K |
| Income Before Tax | -169.22M | 151.32M | -67.49M | -59.46M | -21.65M | -14.19M |
| Income Before Tax Ratio | 0.00% | 0.00% | -356.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -14.12M | 42.12M | -2.45M | -8.61M | -1.62M | 397.00K |
| Net Income | -153.16M | 111.21M | -65.04M | -50.85M | -20.04M | -14.19M |
| Net Income Ratio | 0.00% | 0.00% | -343.35% | 0.00% | 0.00% | 0.00% |
| EPS | -3.69 | 2.46 | -1.47 | -1.17 | -0.46 | -1.24 |
| EPS Diluted | -3.69 | 2.38 | -1.47 | -1.17 | -0.46 | -1.24 |
| Weighted Avg Shares Out | 41.51M | 45.16M | 44.29M | 43.52M | 43.52M | 11.45M |
| Weighted Avg Shares Out (Dil) | 41.55M | 46.64M | 44.29M | 43.52M | 43.52M | 11.45M |
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
Cullinan Oncology to Participate in Upcoming Investor Conferences
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
Why Are Cullinan Oncology Shares Rising Today?
Cullinan Oncology to Present at the Barclays Global Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports